National Kidney Foundation: Study Offers Hope for Patients With Diabetes and Advanced Kidney Disease
September 22, 2020
September 22, 2020
NEW YORK, Sept. 22 (TNSJou) -- The National Kidney Foundation issued the following news release on Sept. 21:
A new study released today in the National Kidney Foundation's American Journal of Kidney Diseases (AJKD) shows that the drug canagliflozin reduces the risk of adverse cardiovascular and kidney outcomes in people with type 2 diabetes, especially for those patients at higher risk of kidney failure.
The post-hoc analysis of the Phase 3, randomized, placebo-controll . . .
A new study released today in the National Kidney Foundation's American Journal of Kidney Diseases (AJKD) shows that the drug canagliflozin reduces the risk of adverse cardiovascular and kidney outcomes in people with type 2 diabetes, especially for those patients at higher risk of kidney failure.
The post-hoc analysis of the Phase 3, randomized, placebo-controll . . .